Stockscreener 앱 받기
0.46%
시간 외 거래:
전일 마감가:
$26.04
열려 있는:
$26.025
하루 거래량:
31.06M
Relative Volume:
0.86
시가총액:
$147.73B
수익:
$63.32B
순이익/손실:
$7.52B
주가수익비율:
19.87
EPS:
1.3043
순현금흐름:
$9.48B
1주 성능:
+1.25%
1개월 성능:
+2.33%
6개월 성능:
+3.51%
1년 성능:
+8.00%
1일 변동 폭
$25.86
$26.28
1주일 범위
$25.70
$26.49
52주 변동 폭
$23.11
$28.75
화이자 Stock (PFE) Company Profile
명칭
Pfizer Inc
전화
(212) 733-2323
주소
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE vs LLY, JNJ, ABBV, NVS, MRK
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
25.92 | 148.19B | 63.32B | 7.52B | 9.48B | 1.3043 |
LLY
Lilly Eli Co
|
1,112.00 | 1.01T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
234.20 | 567.28B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
221.23 | 391.50B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
150.88 | 289.19B | 54.66B | 13.58B | 16.05B | 7.0171 |
MRK
Merck Co Inc
|
115.44 | 283.78B | 65.51B | 8.93B | 14.12B | 3.5532 |
화이자 Stock (PFE) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-02 | 업그레이드 | Argus | Hold → Buy |
| 2026-02-25 | 개시 | RBC Capital Mkts | Underperform |
| 2026-02-20 | 개시 | Barclays | Underweight |
| 2026-02-12 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2026-01-07 | 재개 | UBS | Neutral |
| 2025-12-02 | 재개 | Citigroup | Neutral |
| 2025-11-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-04-22 | 개시 | Cantor Fitzgerald | Neutral |
| 2024-12-10 | 재개 | BofA Securities | Neutral |
| 2024-11-15 | 개시 | Wolfe Research | Underperform |
| 2024-10-25 | 재개 | Citigroup | Neutral |
| 2024-10-17 | 개시 | Bernstein | Mkt Perform |
| 2024-08-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2024-03-22 | 다운그레이드 | Argus | Buy → Hold |
| 2024-02-23 | 개시 | Guggenheim | Buy |
| 2024-01-04 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-10-20 | 재개 | UBS | Neutral |
| 2023-10-16 | 업그레이드 | Jefferies | Hold → Buy |
| 2023-07-17 | 재확인 | JP Morgan | Neutral |
| 2023-07-14 | 개시 | HSBC Securities | Buy |
| 2023-06-29 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-05-11 | 다운그레이드 | Daiwa Securities | Outperform → Neutral |
| 2023-03-06 | 개시 | Jefferies | Hold |
| 2023-02-07 | 업그레이드 | Daiwa Securities | Neutral → Outperform |
| 2023-01-26 | 다운그레이드 | UBS | Buy → Neutral |
| 2023-01-17 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-04 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2022-12-13 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-11-18 | 개시 | Credit Suisse | Outperform |
| 2022-05-23 | 개시 | SVB Leerink | Mkt Perform |
| 2022-04-06 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-01-05 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-01-03 | 재확인 | Bernstein | Mkt Perform |
| 2021-12-20 | 재확인 | Cowen | Outperform |
| 2021-12-17 | 개시 | Goldman | Neutral |
| 2021-12-13 | 업그레이드 | UBS | Neutral → Buy |
| 2021-12-09 | 개시 | Wells Fargo | Overweight |
| 2021-11-19 | 개시 | BMO Capital Markets | Outperform |
| 2021-07-27 | 재개 | Truist | Buy |
| 2021-05-06 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-07 | 재개 | RBC Capital Mkts | Sector Perform |
| 2021-02-04 | 업그레이드 | DZ Bank | Hold → Buy |
| 2020-12-16 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-11-19 | 재개 | Goldman | Neutral |
| 2020-11-10 | 재개 | Bernstein | Mkt Perform |
| 2020-10-12 | 다운그레이드 | Atlantic Equities | Overweight → Neutral |
| 2020-09-29 | 개시 | Berenberg | Hold |
| 2020-06-16 | 개시 | SVB Leerink | Mkt Perform |
| 2020-02-27 | 개시 | Barclays | Equal Weight |
| 2020-02-27 | 업그레이드 | Standpoint Research | Hold → Buy |
| 2020-02-06 | 개시 | Mizuho | Buy |
| 2020-01-07 | 개시 | RBC Capital Mkts | Outperform |
| 2019-10-17 | 재개 | BofA/Merrill | Neutral |
| 2019-07-30 | 다운그레이드 | BofA/Merrill | Buy → Neutral |
| 2019-07-30 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2019-06-04 | 재개 | Morgan Stanley | Overweight |
| 2019-02-20 | 재개 | Citigroup | Neutral |
| 2019-01-31 | 업그레이드 | Argus | Hold → Buy |
| 2019-01-31 | 업그레이드 | Credit Suisse | Neutral → Outperform |
| 2019-01-23 | 다운그레이드 | UBS | Buy → Neutral |
| 2018-12-11 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-11-01 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
모두보기
화이자 주식(PFE)의 최신 뉴스
The Zacks Analyst Blog Highlights Pfizer, Altria, Newmont, Koil Energy and Stratus Properties - Yahoo Finance Singapore
Top Research Reports for Pfizer, Altria & Newmont Corp. - Yahoo Finance
Pfizer Inc. Stock (US7170811035): Analyst Views And Valuation In Focus After Quiet Start To The Week - AD HOC NEWS
Investors heavily search Pfizer Inc. (PFE): Here is what you need to know - MSN
Dr Reddy’s challenges Pfizer with US launch of Bosutinib - The Pharma Letter
Bio Usawa Appoints Dr. Aida Habtezion, Former Chief Medical Officer at Pfizer, to its Board of Directors - Yahoo Finance Singapore
SINOPHARM (01099.HK) Establishes Strategic Partnership with Pfizer, Inc. (PFE.US) - AASTOCKS.com
Pfizer Obesity Pipeline Gains Traction As Berobenatide Data Support Valuation - Yahoo Finance
Pfizer Holds Near $26, Dividend Draws Watch as Drug Prices Cloud Outlook - TechStock²
Comirnaty (Original/Omicron XBB.1.5): Updated mRNA COVID-19 vaccine in focus for US adults - AD HOC NEWS
Pfizer Inc. Stock (US7170811035): Analyst Views and Valuation Under the Microscope - AD HOC NEWS
Pfizer (PFE) Upgraded at RBC Capital. Here is Why - Insider Monkey
How Safe is Bristol Myers Squibb's Dividend? Here's My Honest Take. - The Motley Fool
Pfizer trades around $26 with dividend in focus, drug-price worries linger - TechStock²
Pfizer Pivots Hard: Obesity, Cancer Bets Tempt Investors - TipRanks
Insider trades: Microsoft, Tesla, Pfizer among notable names - Seeking Alpha
Pfizer (PFE): The Best Longevity Stock to Buy Now - Insider Monkey
Pfizer Draws Fresh Focus As Growth Strategy Evolves - Kalkine Media
Pfizer (PFE) Stock Valuation Check As Modest Recent Gains Meet Mixed Multi Year Returns - simplywall.st
Dividend HistoryPfizer (PFE) - Zacks Investment Research
Pfizer Draws Fresh Attention As Pipeline Activity Accelerates - Kalkine Media
Pfizer's New Weight-Loss Data Just Gave Eli Lilly and Novo Nordisk Investors Something to Worry About - Yahoo Finance
Pfizer Still Trades Over $26 as RBC Lift Balances Out Drug-Pricing Concerns - TechStock²
ORIC gains as Stifel resumes at Buy on upcoming Pfizer readout - Seeking Alpha
SpaceX IPO: Value Investors Warn You're Buying A StoryPfizer (NYSE:PFE), SpaceX (NASDAQ:SPCX) - Benzinga
Pfizer Oncology Data Underscore Survival Gains And Valuation Debate - Yahoo Finance
US legislation targets China pharma IP licensing following multi-billion Pfizer, BMS deals - IAM Patent
Sector Gamma AS Sells 392,547 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Stake Lowered by Swiss National Bank - MarketBeat
Pfizer Inc. $PFE Shares Sold by Te Ahumairangi Investment Management Ltd - MarketBeat
Kovack Advisors Inc. Buys 64,044 Shares of Pfizer Inc. $PFE - MarketBeat
ICICI Prudential Asset Management Co Ltd Has $4.11 Million Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by IFM Investors Pty Ltd - MarketBeat
Alps Advisors Inc. Sells 57,526 Shares of Pfizer Inc. $PFE - MarketBeat
First Financial Bankshares Inc Sells 54,776 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Purchased by Aviva PLC - MarketBeat
Pfizer Inc. (NYSE:PFE) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Does New GLP‑1 Data And HYMPAVZI Expansion Reshape The Bull Case For Pfizer (PFE)? - simplywall.st
Pfizer (PFE) Outpaces Stock Market Gains: What You Should Know - Yahoo Finance
Pfizer (NYSE:PFE) Shares Up 2.2%Here's What Happened - MarketBeat
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
PFE Stock Quote Price and Forecast - CNN
This $25 Billion Acquisition Just Unlocked a New Era of Growth for Pfizer — and Why It’s a Flawless Safe-Haven for Retirees - Yahoo Finance
A Sizzling 6.7% Dividend Yield? 1 Under-the-Radar Reason I Am Holding Off on Pfizer Stock at $25 - Yahoo Finance
Pfizer’s New Phase 1 PF-07799544 Study Adds Quiet Depth to Its R&D Pipeline - TipRanks
Why Pfizer Stock Popped Today - The Globe and Mail
Pfizer Shares Edge Higher on RBC Upgrade, German Pricing Risk in Focus - TechStock²
Lexicon Pharmaceuticals vs Pfizer: Comparing a Small Biotech with a Global DrugmakerNews and Statistics - IndexBox
Pfizer shares climb 3.2% as investors digest expanded U.S. label for HYMPAVZI - Quiver Quantitative
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026? - Yahoo Finance
Pfizer Inc. $PFE Stock Position Lowered by Townsquare Capital LLC - MarketBeat
화이자 (PFE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.40%
0.23%
자본화:
|
볼륨(24시간):